Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSEIDON Group 2: Personalized Addition of Recombinant LH in Suboptimal Responders >35 Years
2024-514035-19-00Phase 4Authorised
- Sponsor
- Fundació Santiago Dexeus Font
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of luteinizing hormone in infertility (2 arms), sponsored by Fundació Santiago Dexeus Font. Primary endpoints: Serum progesterone level on the day of ovulation triggering and Progesterone-to-estradiol ratio (P4/E2) on the day of ovulation triggering. Planned start Sep 2024; status: authorised.
02
Drugs
luteinizing hormone
03
Conditions
infertility
Beyond the preview
Go deeper on 2024-514035-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514035-19-00.